Recent studies have highlighted the significance of lomustine, an alkylating agent, in the treatment of newly diagnosed MGMT methylated glioblastoma, despite previous assertions of limited data supporting its definitive interaction with MGMT. Here, MGMT is linked to glioblastoma.